{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T17:32:32Z","timestamp":1791048752177,"version":"4.1.0"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2022,2,22]],"date-time":"2022-02-22T00:00:00Z","timestamp":1645488000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,3,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Atorvastatin and sacubitril\/valsartan (Entresto\u2122) have been cornerstones in managing patients with coronary artery disease and heart failure (HF). We report a case of life-threatening rhabdomyolysis associated with the co-administration of atorvastatin and sacubitril\/valsartan.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Case summary<\/jats:title>\n                  <jats:p>A 58-year-old male with coronary heart disease and chronic HF treated with the optimal dose of atorvastatin and other cardiovascular medications was frequently admitted for acute decompensation of HF. We decided to optimize his condition by adding sacubitril\/valsartan to his treatment regime. He presented to our outpatient clinic with worsening myalgia and oliguria 6 days later. He was readmitted with markedly elevated serum creatinine kinase (CK) (94\u200a850 U\/L; normal range 32\u2013294 U\/L), deranged liver function tests, and acute kidney injury. We withheld atorvastatin and sacubitril\/valsartan and treated him with renal replacement therapy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Discussion<\/jats:title>\n                  <jats:p>Sacubitril inhibits the excretion of statins, thereby elevating serum statin concentration and increasing the likelihood of developing muscle-related toxicity. Co-administration of atorvastatin and sacubitril\/valsartan should be monitored closely with laboratory investigations of CK and liver and renal function. The physician may consider starting low-dose atorvastatin at 20 mg daily in combination with sacubitril\/valsartan 24 mg\/26 mg twice daily and titrating accordingly to optimal doses. Rosuvastatin could be an alternative to atorvastatin, as it has less drug\u2013drug interaction with sacubitril, thereby reducing the adverse effect.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ehjcr\/ytac091","type":"journal-article","created":{"date-parts":[[2022,2,22]],"date-time":"2022-02-22T12:14:39Z","timestamp":1645532079000},"source":"Crossref","is-referenced-by-count":3,"title":["Approaches to management of rhabdomyolysis as the adverse effect of drug interaction between atorvastatin and sacubitril\/valsartan: a case report"],"prefix":"10.1093","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8252-1923","authenticated-orcid":false,"given":"Kelvin Shenq Woei","family":"Siew","sequence":"first","affiliation":[{"name":"Division of Cardiology, Department of Medicine, University Malaya Medical Centre, Jln Profesor Diraja Ungku Aziz, 59100 Kuala Lumpur, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7444-9631","authenticated-orcid":false,"given":"Muhammad Imran","family":"Abdul Hafidz","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, University Malaya Medical Centre, Jln Profesor Diraja Ungku Aziz, 59100 Kuala Lumpur, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatimah Zahrah Binti","family":"Mohd Zaidan","sequence":"additional","affiliation":[{"name":"Department of Primary Care Medicine, University Malaya Medical Centre, Jln Profesor Diraja Ungku Aziz, 59100 Kuala Lumpur, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1768-2330","authenticated-orcid":false,"given":"Mohd Firdaus bin","family":"Hadi","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, University Malaya Medical Centre, Jln Profesor Diraja Ungku Aziz, 59100 Kuala Lumpur, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,2,22]]},"reference":[{"key":"2022030409594132600_ytac091-B1","doi-asserted-by":"crossref","first-page":"e009517","DOI":"10.1161\/JAHA.118.009517","article-title":"High intensity versus non-high-intensity statins in patients achieving low density lipoprotein cholesterol goal after percutaneous coronary intervention","volume":"7","author":"Kim","year":"2018","journal-title":"JAHA"},{"key":"2022030409594132600_ytac091-B2","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1161\/CIRCRESAHA.118.312782","article-title":"Statin toxicity","volume":"124","author":"Ward","year":"2019","journal-title":"Circ Res"},{"key":"2022030409594132600_ytac091-B3","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin\u2013neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"2022030409594132600_ytac091-B4","first-page":"58","article-title":"Rhabdomyolysis: pathogenesis, diagnosis, and treatment","volume":"15","author":"Torres","year":"2015","journal-title":"Ochsner J"},{"key":"2022030409594132600_ytac091-B5","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJM199811053391902","article-title":"Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels","volume":"339","author":"Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group","year":"1998","journal-title":"N Engl J Med"},{"key":"2022030409594132600_ytac091-B6","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1253\/circj.CJ-18-1321","article-title":"Relative effect of current intensive lipid-lowering drugs on cardiovascular outcomes in secondary prevention\u2014a meta-analysis of 12 randomized trials","volume":"83","author":"Wang","year":"2019","journal-title":"Circ J"},{"key":"2022030409594132600_ytac091-B7","doi-asserted-by":"crossref","first-page":"8882706","DOI":"10.1155\/2021\/8882706","article-title":"Risk factors associated with statin-associated muscle symptoms in patients attending a specialized regional lipid clinic","volume":"2021","author":"Saeed","year":"2021","journal-title":"J Lipids"},{"key":"2022030409594132600_ytac091-B8","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1111\/bcp.13950","article-title":"Severe rosuvastatin accumulation with rhabdomyolysis due to drug interactions and low cardiac output syndrome","volume":"85","author":"Previsdomini","year":"2019","journal-title":"Br J Clin Pharmacol"},{"key":"2022030409594132600_ytac091-B9","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s40800-016-0036-6","article-title":"Rhabdomyolysis after coadministration of atorvastatin and sacubitril\/valsartan (Entresto\u2122) in a 63-year-old woman","volume":"3","author":"Faber","year":"2016","journal-title":"Drug Saf Case Rep"},{"key":"2022030409594132600_ytac091-B10","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.22374\/cjgim.v15i1.343","article-title":"Rhabdomyolysis as a side effect of the drug interaction between atorvastatin and sacubitril\/valsartan","volume":"15","author":"Chan","year":"2020","journal-title":"Can J Gen Int Med"},{"key":"2022030409594132600_ytac091-B11","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3390\/diseases7020038","article-title":"A rare adverse event of rhabdomyolysis caused by sacubitril\/valsartan","volume":"7","author":"Rawla","year":"2019","journal-title":"Diseases"},{"key":"2022030409594132600_ytac091-B12","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s13318-016-0349-y","article-title":"Assessment of drug\u2013drug interaction potential between atorvastatin and LCZ696, a novel angiotensin receptor neprilysin inhibitor, in healthy Chinese male subjects","volume":"42","author":"Ayalasomayajula","year":"2017","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"2022030409594132600_ytac091-B13","doi-asserted-by":"crossref","first-page":"e234","DOI":"10.1111\/j.1755-5922.2011.00290.x","article-title":"The role of OATP1B1 and BCRP in pharmacokinetics and DDI of novel statins","volume":"30","author":"Hua","year":"2012","journal-title":"Cardiovasc Ther"},{"key":"2022030409594132600_ytac091-B14","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1002\/pds.3199","article-title":"Clinical importance of the drug interaction between statins and CYP3A4 inhibitors: a retrospective cohort study in The Health Improvement Network","volume":"21","author":"Rowan","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2022030409594132600_ytac091-B15","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/j.xphs.2017.01.007","article-title":"Evaluation of drug-drug interaction potential between sacubitril\/valsartan (LCZ696) and statins using a physiologically based pharmacokinetic model","volume":"106","author":"Lin","year":"2017","journal-title":"J Pharm Sci"},{"key":"2022030409594132600_ytac091-B16","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1001\/jama.2016.15450","article-title":"Statin use for the primary prevention of cardiovascular disease in adults: US Preventive Services Task Force Recommendation Statement","volume":"316","author":"Force","year":"2016","journal-title":"JAMA"},{"key":"2022030409594132600_ytac091-B17","volume-title":"U.S. Preventive Services Task Force Evidence Syntheses, Formerly Systematic Evidence Reviews. Statin Use for the Prevention of Cardiovascular Disease in Adults: A Systematic Review for the US Preventive Services Task Force","author":"Chou","year":"2016"},{"key":"2022030409594132600_ytac091-B18","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1001\/jamacardio.2018.3957","article-title":"Estimated 5-year number needed to treat to prevent cardiovascular death or heart failure hospitalization with angiotensin receptor-neprilysin inhibition vs standard therapy for patients with heart failure with reduced ejection fraction: an analysis of data from the PARADIGM-HF trial","volume":"3","author":"Srivastava","year":"2018","journal-title":"JAMA Cardiol"},{"key":"2022030409594132600_ytac091-B19","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s10741-018-9757-1","article-title":"Practical guidance on the use of sacubitril\/valsartan for heart failure","volume":"24","author":"Sauer","year":"2019","journal-title":"Heart Fail Rev"},{"key":"2022030409594132600_ytac091-B20","doi-asserted-by":"crossref","first-page":"17","DOI":"10.4137\/CMC.S4324","article-title":"Rosuvastatin: a review of the pharmacology and clinical effectiveness in cardiovascular disease","volume":"6","author":"Luvai","year":"2012","journal-title":"Clin Med Insights Cardiol"},{"key":"2022030409594132600_ytac091-B21","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1007\/s40262-017-0543-3","article-title":"Clinical pharmacokinetics of sacubitril\/valsartan (LCZ696): a novel angiotensin receptor-neprilysin inhibitor","volume":"56","author":"Ayalasomayajula","year":"2017","journal-title":"Clin Pharmacokinet"},{"key":"2022030409594132600_ytac091-B22","doi-asserted-by":"crossref","first-page":"e468","DOI":"10.1161\/CIR.0000000000000456","article-title":"Recommendations for management of clinically significant drug-drug interactions with statins and select agents used in patients with cardiovascular disease: a scientific statement from the American Heart Association","volume":"134","author":"Wiggins","year":"2016","journal-title":"Circulation"},{"key":"2022030409594132600_ytac091-B23","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1472-8206.2004.00299.x","article-title":"Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update","volume":"19","author":"Schachter","year":"2005","journal-title":"Fundam Clin Pharmacol"}],"container-title":["European Heart Journal - Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjcr\/advance-article-pdf\/doi\/10.1093\/ehjcr\/ytac091\/42576939\/ytac091.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcr\/article-pdf\/6\/3\/ytac091\/42706293\/ytac091.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcr\/article-pdf\/6\/3\/ytac091\/42706293\/ytac091.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,4]],"date-time":"2022-03-04T10:00:13Z","timestamp":1646388013000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjcr\/article\/doi\/10.1093\/ehjcr\/ytac091\/6534331"}},"subtitle":[],"editor":[{"given":"Daniel","family":"Bromage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]},{"given":"Edgar Francisco","family":"Carrizales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]},{"given":"Ching-Hui","family":"Sia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]},{"given":"Zhiyu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]},{"given":"Katharine","family":"Kott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,2,22]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3,2]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjcr\/ytac091","relation":{},"ISSN":["2514-2119"],"issn-type":[{"value":"2514-2119","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,3,1]]},"published":{"date-parts":[[2022,2,22]]},"article-number":"ytac091"}}